SCHEMBL6628518

SCHEMBL6628518

CC(=O)C(Cl)c1cccc(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ACP3 P15309 1/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ADRA1D P25100 1/20 0.41
PARP1 P09874 1/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 2/20 0.41
TRPM8 Q7Z2W7 1/20 0.40
BRD4 O60885 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
HTT P42858 1/20 0.40
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2649566 0.82 ACP3 (0.47) ACP3MEN1KMT2AADRA1DPARP1
SCHEMBL10939067 0.82 MEN1 (0.53) ACP3MEN1KMT2APARP1ALDH1A1
SCHEMBL22917154 0.82 ACP3 (0.47) ACP3MEN1KMT2AADRA1DPARP1
SCHEMBL7283486 0.81 PARP1 (0.50) ACP3MEN1KMT2AADRA1DPARP1
SCHEMBL6626050 0.81 ACHE (0.46) ACP3MEN1KMT2APARP1ALDH1A1
SCHEMBL12907075 0.81 ACP3 (0.46) ACP3MEN1KMT2AADRA1DPARP1
SCHEMBL15695557 0.81 PTGS1 (0.46) ACP3MEN1KMT2AADRA1DALDH1A1
SCHEMBL12658713 0.81 ACP3 (0.46) ACP3MEN1KMT2AADRA1DPARP1
SCHEMBL20535015 0.79 ACP3 (0.45) ACP3MEN1KMT2AADRA1DPARP1
SCHEMBL30826369 0.79 ACP3 (0.45) ACP3MEN1KMT2AADRA1DPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1432706-A2 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS Bayer Pharmaceuticals Corporation (US) 2004-06-30 EP disclosed
WO-2003027085-A2 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed